REACT SHOCK试验方案与统计分析计划:一项比较个体化血压目标与标准血压目标在危重症休克患者中应用的多中心随机对照试验
REACT SHOCK RCT是一项国际多中心、平行组、随机、标准治疗对照的优效性试验,拟在澳大利亚、爱尔兰、新加坡、英国和美国的至多35个ICU纳入1260例接受血管升压药治疗的非出血性休克患者,1:1随机分配至个体化平均动脉压目标(55至95 mmHg)或标准治疗(默认平均动脉压目标65 mmHg),主要终点为14天全因死亡率。
要点
- 纳入接受血管升压药治疗的非出血性休克ICU患者1260例,1:1随机分组。
- 个体化平均动脉压目标范围为55至95 mmHg,标准治疗默认目标为65 mmHg。
- 主要终点为14天全因死亡率,预计2028年完成招募。
核心结论
- REACT SHOCK RCT是首个旨在确定个体化血压目标策略是否优于标准治疗的危重症休克患者国际多中心随机临床试验。
- 该试验将产生可能影响当前ICU休克管理中平均动脉压目标推荐意见的证据。
研究设计与样本
- 国际、多中心、平行组、随机、标准治疗对照的临床优效性试验,计划在澳大利亚、爱尔兰、新加坡、英国和美国的至多35个ICU开展。
- 共纳入1260例在ICU接受血管升压药治疗的非出血性休克患者,按1:1比例随机分配至个体化平均动脉压目标组或标准治疗组。
- 个体化平均动脉压目标依据近3年内2至5次病前血压读数的平均值确定,平均动脉压目标范围为55至95 mmHg;标准治疗默认平均动脉压目标为65 mmHg。
- 预计2028年完成招募。
主要发现
- 主要终点为14天全因死亡率。
- 次要终点包括第14天主要不良肾脏事件、90天全因死亡率、14天和90天生存时间以及第28天无肾脏替代治疗天数。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Critically ill patients with shock receiving vasopressor or inotrope therapy in ICU are often exposed to relative hypotension, which is quantified as percentage blood pressure deficit relative to usual pre-illness blood pressure. Whether minimising such blood pressure deficit, by adjusting blood pressure targets according to patients' pre-illness blood pressure (individualised blood pressure target strategy), can improve clinical outcomes remains unclear. Therefore, we are conducting a multicenter randomised controlled trial, the REACT SHOCK RCT, comparing individualised blood pressure targets to standard care among critically ill patients with shock. METHODS: The REACT SHOCK RCT is an international, multicenter, parallel-group, randomised, standard-care controlled, clinical superiority trial that will be conducted in up to 35 ICUs in Australia, Ireland, Singapore, UK and USA. In total, 1260 patients, receiving vasopressor therapy for non-haemorrhagic shock in ICU, will be randomly assigned to individualised mean arterial blood pressure (MAP) targets (determined as an average of 2-5 recent pre-illness blood pressure readings within last 3 years, with a MAP target range of 55 to 95 mmHg) or standard care (default MAP target of 65 mmHg) in a 1:1 ratio. The REACT SHOCK RCT is anticipated to complete recruitment by 2028. The primary endpoint is all-cause 14-day mortality. Secondary endpoints are major adverse kidney events by day 14, all-cause 90-day mortality, survival time to 14 days and 90 days, and renal replacement therapy free days by day 28. DISCUSSION: The REACT SHOCK RCT is the first international multicenter randomised clinical trial designed to ascertain whether an individualised blood pressure target strategy is superior to standard care for critically ill patients with shock. This trial will generate evidence that may influence current recommendations for MAP targets during management of shock in ICU. The pre-specified protocol summary and statistical analysis plan are presented here. TRIAL REGISTRATION: Prospectively registered on Australian and New Zealand Clinical Trials Registry (ANZCTRN 12623000044628); ClinicalTrials.gov ID NCT05850962 dated 29th April 2023.
引用
- Panwar R, Gibberd A, Oldmeadow C, et al. REACT SHOCK trial protocol and analysis plan-a multicenter randomised controlled trial comparing individualised blood pressure target versus standard blood pressure target among critically ill patients with shock. Trials. 2025. PMID: 41088147. doi:10.1186/s13063-025-09142-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。